The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance

@inproceedings{Alidzanovic2016TheVR,
  title={The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance},
  author={Lejla Alidzanovic and P Starlinger and Dominic Schauer and Thomas C Maier and Alexandra Feldman and Elisabeth Buchberger and Judith Stift and Ulrike K{\"o}ck and Lorand Pop and Birgit Gruenberger and Thomas Gruenberger and Christine Brostjan},
  booktitle={Oncotarget},
  year={2016}
}
Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have been proposed but not verified in the clinical setting. Hence, we evaluated sixty patients with colorectal cancer metastases for changes in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS